FR2644061A1 - Composition a activite antiagregante plaquettaire utilisable en therapeutique - Google Patents

Composition a activite antiagregante plaquettaire utilisable en therapeutique Download PDF

Info

Publication number
FR2644061A1
FR2644061A1 FR8903138A FR8903138A FR2644061A1 FR 2644061 A1 FR2644061 A1 FR 2644061A1 FR 8903138 A FR8903138 A FR 8903138A FR 8903138 A FR8903138 A FR 8903138A FR 2644061 A1 FR2644061 A1 FR 2644061A1
Authority
FR
France
Prior art keywords
taurine
acetylsalicylic acid
composition
acid
platelet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR8903138A
Other languages
English (en)
French (fr)
Other versions
FR2644061B1 (enExample
Inventor
Jesus Covarrubias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MATIVELLE
Original Assignee
MATIVELLE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR8903138A priority Critical patent/FR2644061A1/fr
Application filed by MATIVELLE filed Critical MATIVELLE
Priority to CA002027593A priority patent/CA2027593C/fr
Priority to EP90400605A priority patent/EP0387140B1/fr
Priority to PCT/FR1990/000149 priority patent/WO1990010447A1/fr
Priority to DE69009538T priority patent/DE69009538T2/de
Priority to JP2504738A priority patent/JP2935138B2/ja
Priority to AT90400605T priority patent/ATE106733T1/de
Priority to KR1019900702419A priority patent/KR0169118B1/ko
Priority to ES90400605T priority patent/ES2058832T3/es
Priority to MX019819A priority patent/MX174250B/es
Publication of FR2644061A1 publication Critical patent/FR2644061A1/fr
Application granted granted Critical
Publication of FR2644061B1 publication Critical patent/FR2644061B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR8903138A 1989-03-10 1989-03-10 Composition a activite antiagregante plaquettaire utilisable en therapeutique Granted FR2644061A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR8903138A FR2644061A1 (fr) 1989-03-10 1989-03-10 Composition a activite antiagregante plaquettaire utilisable en therapeutique
EP90400605A EP0387140B1 (fr) 1989-03-10 1990-03-06 Composition à activité anti-agrégante plaquettaire utilisable en thérapeutique
PCT/FR1990/000149 WO1990010447A1 (fr) 1989-03-10 1990-03-06 Composition a activite anti-agregante plaquettaire utilisable en therapeutique
DE69009538T DE69009538T2 (de) 1989-03-10 1990-03-06 In der Therapeutik anwendbare Zusammensetzung mit aggregationshemmender Wirkung auf Blutplättchen.
CA002027593A CA2027593C (fr) 1989-03-10 1990-03-06 Composition a activite anti-agregante plaquettaire utilisable en therapeutique
JP2504738A JP2935138B2 (ja) 1989-03-10 1990-03-06 治療に有用な血小板抗凝集効果を有する新しい組成物
AT90400605T ATE106733T1 (de) 1989-03-10 1990-03-06 In der therapeutik anwendbare zusammensetzung mit aggregationshemmender wirkung auf blutplättchen.
KR1019900702419A KR0169118B1 (ko) 1989-03-10 1990-03-06 치료에 유용한 혈소판 항-응집 효과를 갖는 조성물
ES90400605T ES2058832T3 (es) 1989-03-10 1990-03-06 Composicion con actividad anti-agregante plaquetaria utilizable en terapeutica.
MX019819A MX174250B (es) 1989-03-10 1990-03-09 Composicion con actividad antiagregante de plaqueta util en terapias

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8903138A FR2644061A1 (fr) 1989-03-10 1989-03-10 Composition a activite antiagregante plaquettaire utilisable en therapeutique

Publications (2)

Publication Number Publication Date
FR2644061A1 true FR2644061A1 (fr) 1990-09-14
FR2644061B1 FR2644061B1 (enExample) 1994-04-22

Family

ID=9379557

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8903138A Granted FR2644061A1 (fr) 1989-03-10 1989-03-10 Composition a activite antiagregante plaquettaire utilisable en therapeutique

Country Status (10)

Country Link
EP (1) EP0387140B1 (enExample)
JP (1) JP2935138B2 (enExample)
KR (1) KR0169118B1 (enExample)
AT (1) ATE106733T1 (enExample)
CA (1) CA2027593C (enExample)
DE (1) DE69009538T2 (enExample)
ES (1) ES2058832T3 (enExample)
FR (1) FR2644061A1 (enExample)
MX (1) MX174250B (enExample)
WO (1) WO1990010447A1 (enExample)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Rote Liste", 2 mars 1961, page 396, Editio Cantor, Aulendorf, DE *
CHEMICAL ABSTRACTS, vol. 73, no. 9, 31 août 1970, page 154, résumé no. 43479n, Columbus, Ohio, US; K. MORISAKA et al.: "Correlation between behavior of taurine or glycine and their accelerative effect on absorption of salicylic acid derivatives in gastrointestinal tract of rat", & YAKUGAKU ZASSHI 1970, 90(5), 634-8 *
CHEMICAL ABSTRACTS, vol. 83, no. 13, 29 septembre 1975, pages 35-36, résumé no. 108332n, Columbus, Ohio, US; K. HORISAKA et al.: "Effect of taurine analogs on the analgesic and antipyretic effects of aspirin", & IGAKU TO SEIBUTSUGAKU 1974, 89(6), 407-11 *
CHEMICAL ABSTRACTS, vol. 94, no. 13, 30 mars 1981, page 158, résumé no. 96860v, Columbus, Ohio, US; T. KIMURA et al.: "Effect of taurine on gastrointestinal absorption of drugs", & GANRYU AMINOSAN 1979, 2, 179-86 *
CHEMICAL ABSTRACTS, vol. 95, no. 7, 17 août 1981, page 41, résumé no. 54819d, Columbus, Ohio, US; T. KIMURA et al.: "Effect of taurine on drug absorption from the rat gastrointestinal tract", & J. PHARMACOBIO-DYN. 1981, 4(1), 35-41 *

Also Published As

Publication number Publication date
JPH03504509A (ja) 1991-10-03
DE69009538T2 (de) 1995-01-12
KR0169118B1 (ko) 1999-01-15
EP0387140B1 (fr) 1994-06-08
WO1990010447A1 (fr) 1990-09-20
ES2058832T3 (es) 1994-11-01
FR2644061B1 (enExample) 1994-04-22
ATE106733T1 (de) 1994-06-15
JP2935138B2 (ja) 1999-08-16
EP0387140A1 (fr) 1990-09-12
CA2027593A1 (fr) 1990-09-11
KR920700037A (ko) 1992-02-19
DE69009538D1 (de) 1994-07-14
MX174250B (es) 1994-05-02
CA2027593C (fr) 2001-01-02

Similar Documents

Publication Publication Date Title
EP1908461B1 (fr) Utilisation de l'énantiomère (1S, 2R) du milnacipran pour la préparation d'un médicament
EP2305225A1 (fr) Utilisation de l'enantiomere (1s, 2r) du milnacipran pour la preparation d'un medicament
EP0272177B1 (fr) Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine
EP1656131B1 (fr) Utilisation de la betaine pour le traitement de la claudication intermittente
CA2491848A1 (en) Pharmaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor
FR2641189A1 (fr) Compositions pharmaceutiques contenant de l'acide acetyl salicylique et de la vitamine b6
US4794112A (en) Acetaminophen/hydroxyzine analgesic combinations
Billups et al. Mibefradil: a new class of calcium-channel antagonists
CA2027593C (fr) Composition a activite anti-agregante plaquettaire utilisable en therapeutique
Jensen et al. Clinical trial of nimodipine for single attacks of classic migraine
FR2576787A1 (fr) Formulation a liberation prolongee contenant des alcaloides de l'ergot de seigle
EP0413694B1 (fr) Preparations medicamenteuses cardio-protectrices comprenant l'amiodarone, un derive nitre, notamment le dinitrate d'isosorbide et facultativement un beta-bloqueur
US20110117070A1 (en) Compositions and methods for treating headache
WO1998024434A1 (fr) Nouvelle application therapeutique d'un derive de la thienylcyclohexylamine
BE901111A (fr) Composition pharmaceutiques a liberation prolongee, leur procede de preparation et leur utilisation.
EP1553944A1 (fr) Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l histamine
WO1998035670A1 (fr) Produit contenant de l'idazoxan et de la 1-dopa comme preparation pharmaceutique combinee utilise pour la maladie de parkinson
HUP0201650A2 (hu) Amino-tetralin-származékok alkalmazása szív- és érrendszeri betegségek gyógykezelésére használható gyógyszerek előállítására
Palmer et al. Triethanolamine Trinitrate—Clinical Trial
MC2019A1 (fr) Composition pharmaceutique anti-hypertensive combinee
EP0287469B1 (fr) Assocation renfermant à titre de principes actifs, un analgésique central et la forskoline
LU86290A1 (fr) Compositions pharmaceutiques a base de 3-aminopropoxyindoles
EP0412877A1 (fr) Nouvelle forme galénique orale améliorant la biodisponibilité
EP0818997A1 (fr) Compositions comprenant l'amiodarone et le betaxolol
FR2726763A1 (fr) Nouveaux medicaments cardioprotecteurs et leur procede de preparation

Legal Events

Date Code Title Description
ST Notification of lapse